424 related articles for article (PubMed ID: 34095756)
1. Treatment for Relapsed/Refractory Acute Myeloid Leukemia.
Thol F; Heuser M
Hemasphere; 2021 Jun; 5(6):e572. PubMed ID: 34095756
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
3. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
4. How I treat refractory and relapsed acute myeloid leukemia.
Thol F; Döhner H; Ganser A
Blood; 2024 Jan; 143(1):11-20. PubMed ID: 37944143
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Relapsed or Refractory
Bertoli S; Dumas PY; Bérard E; Largeaud L; Bidet A; Delabesse E; Tavitian S; Gadaud N; Leguay T; Leroy H; Rieu JB; Vial JP; Vergez F; Lechevalier N; Luquet I; Klein E; Sarry A; Grande AC; Récher C; Pigneux A
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218221
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profile of gilteritinib (Xospata
Mori M; Hidaka K
Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479
[TBL] [Abstract][Full Text] [Related]
7. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E; Cohen I; Amitai I; Ram R; Frisch A; Nachmias B; Canaani J; Moshe Y; Krayem B; Aumann S; Henig I; Vainstein V; Shargian L; Ganzel C; Yeshurun M; Levi I; Raanani P; Akria L; Ofran Y; Shimony S; Wolach O
Br J Haematol; 2024 May; ():. PubMed ID: 38782575
[TBL] [Abstract][Full Text] [Related]
8. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
10. [Novel Strategies to Treat Acute Myeloid Leukemia].
Gediga MHE; Middeke JM; Ruhnke L
Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
[TBL] [Abstract][Full Text] [Related]
11. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
12.
Megías-Vericat JE; Ballesta-López O; Barragán E; Montesinos P
Blood Lymphat Cancer; 2019; 9():19-32. PubMed ID: 31413655
[TBL] [Abstract][Full Text] [Related]
13. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
14. Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients.
Mima F; Fuji S; Shibata K; Kida S; Tsutsumi K; Tada Y; Shingai Y; Yuda S; Yokota T; Ishikawa J
Blood Cell Ther; 2023 Aug; 6(3):77-79. PubMed ID: 38146352
[TBL] [Abstract][Full Text] [Related]
15. Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Culos K; Byrne M
Clin Hematol Int; 2019 Jun; 1(2):94-100. PubMed ID: 34595416
[TBL] [Abstract][Full Text] [Related]
16. Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.
Liberatore C; Di Ianni M
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834466
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
[TBL] [Abstract][Full Text] [Related]
18. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
19. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
20. Progress in the problem of relapsed or refractory acute myeloid leukemia.
Mims AS; Blum W
Curr Opin Hematol; 2019 Mar; 26(2):88-95. PubMed ID: 30640734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]